Fondazione Italiana Diabete Onlus   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Milan Italy (2009)

Organization Overview

First Clinical Trial
2009
NCT01148446
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Ematologia, Candiolo Cancer Institute. FPO-IRCCS | Fondazione Italiana Linfomi ONLUS | Fondazione Italiana Sindromi Mielodisplastiche Onlus

Active Ingredients

Drugs in Phase 3 Trials (29)

allogeneic adipose derived mesenchymal stem cell (1 trial)

bendamustine (treanda) (10 trials)

bleomycin (blenoxane) (5 trials)

bortezomib (velcade) (4 trials)

carmustine (bicnu) (1 trial)

cisplatin (platinol) (2 trials)

cyclophosphamide (cytoxan) (14 trials)

cytarabine (cytosar-u) (6 trials)

dacarbazine (dtic-dome) (5 trials)

doxorubicin (Doxil) (17 trials)

epirubicin (ellence) (1 trial)

epoetin (Epogen) (1 trial)

etoposide (vepesid) (5 trials)

filgrastim (neupogen) (3 trials)

fludarabine (fludara) (1 trial)

fludeoxyglucose f-18 (1 trial)

ibritumomab tiuxetan (zevalin) (2 trials)

lenalidomide (revlimid) (7 trials)

mitoxantrone (novantrone) (3 trials)

multivitamins (1 trial)

obinutuzumab (gazyva) (6 trials)

prednisone (meticorten) (13 trials)

procarbazine (matulane) (1 trial)

rituximab (rituxan) (22 trials)

sargramostim (leukine) (2 trials)

urea (4 trials)

vinblastine (velban) (6 trials)

vincristine (oncovin) (13 trials)

vitamin d3 (1 trial)

Drugs in Phase 2 Trials (29)

allogeneic pancreatic islet cells (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

arsenic trioxide (trisenox) (1 trial)

brentuximab vedotin (adcetris) (5 trials)

carboplatin (paraplatin) (1 trial)

carfilzomib (kyprolis) (1 trial)

clofarabine (clolar) (1 trial)

copanlisib (aliqopa) (1 trial)

daratumumab (darzalex) (2 trials)

decitabine (dacogen) (1 trial)

deferasirox (exjade) (1 trial)

dexamethasone (2 trials)

gemcitabine (gemzar) (1 trial)

ibrutinib (imbruvica) (2 trials)

idelalisib (zydelig) (1 trial)

ifosfamide (ifex) (1 trial)

ledipasvir (Harvoni) (1 trial)

loncastuximab (1 trial)

mesna (mesnex) (1 trial)

ofatumumab (arzerra) (1 trial)

panobinostat (farydak) (1 trial)

ribavirin (virazole) (1 trial)

romidepsin (istodax) (2 trials)

sirolimus (rapamune) (2 trials)

sofosbuvir (sovaldi) (1 trial)

venetoclax (venclexta) (2 trials)

vildagliptin (1 trial)

vinorelbine (navelbine) (1 trial)

vitamin c (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aggression (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hodgkin Disease (Phase 3)

Immunoblastic Lymphadenopathy (Phase 2)

Iron Overload (Phase 2)

Leukemia (Phase 2)

Leukemia, Myelomonocytic, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Lymphatic Diseases (Phase 2)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Large-Cell, Anaplastic (Phase 2)

Lymphoma, Mantle-Cell (Phase 3)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Myelodysplastic Syndromes (Phase 3)

Preleukemia (Phase 3)

Syndrome (Phase 3)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 59
  • # of Trial APIs: 58